Cambridge Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.14M | Sell |
8,520
-40
| -0.5% | -$8.61K | 0.37% | 43 |
|
|
2026
Q1 | $1.86M | Sell |
8,560
-45
| -0.5% | -$9.98K | 0.36% | 44 |
|
|
2025
Q4 | $1.97M | Sell |
8,605
-15
| -0.2% | -$3.42K | 0.37% | 41 |
|
|
2025
Q3 | $2M | Sell |
8,620
-82
| -0.9% | -$16.7K | 0.39% | 41 |
|
|
2025
Q2 | $1.62M | Sell |
8,702
-18
| -0.2% | -$3.35K | 0.34% | 49 |
|
|
2025
Q1 | $1.83M | Sell |
8,720
-159
| -2% | -$30.9K | 0.4% | 41 |
|
|
2024
Q4 | $1.58M | Buy |
8,879
+104
| +1% | +$19.1K | 0.35% | 47 |
|
|
2024
Q3 | $1.73M | Sell |
8,775
-65
| -0.7% | -$12.1K | 0.38% | 43 |
|
|
2024
Q2 | $1.52M | Buy |
8,840
+65
| +0.7% | +$10.8K | 0.35% | 45 |
|
|
2024
Q1 | $1.6M | Sell |
8,775
-600
| -6% | -$103K | 0.38% | 43 |
|
|
2023
Q4 | $1.45M | Sell |
9,375
-200
| -2% | -$29.2K | 0.37% | 43 |
|
|
2023
Q3 | $1.43M | Sell |
9,575
-505
| -5% | -$74.1K | 0.38% | 42 |
|
|
2023
Q2 | $1.36M | Sell |
10,080
-1,085
| -10% | -$159K | 0.35% | 44 |
|
|
2023
Q1 | $1.78M | Buy |
11,165
+50
| +0.4% | +$7.64K | 0.46% | 31 |
|
|
2022
Q4 | $1.8M | Sell |
11,115
-350
| -3% | -$53.7K | 0.48% | 31 |
|
|
2022
Q3 | $1.54M | Sell |
11,465
-50
| -0.4% | -$7.17K | 0.44% | 35 |
|
|
2022
Q2 | $1.76M | Sell |
11,515
-233
| -2% | -$35.6K | 0.48% | 29 |
|
|
2022
Q1 | $1.9M | Sell |
11,748
-37
| -0.3% | -$5.38K | 0.45% | 30 |
|
|
2021
Q4 | $1.6M | Buy |
11,785
+400
| +4% | +$47.3K | 0.36% | 43 |
|
|
2021
Q3 | $1.23M | Sell |
11,385
-231
| -2% | -$26.4K | 0.3% | 58 |
|
|
2021
Q2 | $1.31M | Sell |
11,616
-274
| -2% | -$30.9K | 0.32% | 57 |
|
|
2021
Q1 | $1.29M | Buy |
11,890
+1
| +0% | +$107 | 0.33% | 50 |
|
|
2020
Q4 | $1.27M | Buy |
11,889
+1
| +0% | +$96 | 0.34% | 51 |
|
|
2020
Q3 | $1.04M | Buy |
11,888
+2
| +0% | +$188 | 0.31% | 58 |
|
|
2020
Q2 | $1.17M | Buy |
11,886
+1
| +0% | +$88 | 0.37% | 47 |
|
|
2020
Q1 | $906K | Buy |
11,885
+525
| +5% | +$44.7K | 0.33% | 54 |
|
|
2019
Q4 | $1.01M | Sell |
11,360
-400
| -3% | -$33.2K | 0.31% | 60 |
|
|
2019
Q3 | $890K | Sell |
11,760
-60
| -0.5% | -$4.11K | 0.29% | 60 |
|
|
2019
Q2 | $860K | Hold |
11,820
| – | – | 0.28% | 64 |
|
|
2019
Q1 | $953K | Sell |
11,820
-50
| -0.4% | -$4.09K | 0.32% | 54 |
|
|
2018
Q4 | $1.09M | Buy |
11,870
+100
| +0.8% | +$8.79K | 0.41% | 45 |
|
|
2018
Q3 | $1.11M | Sell |
11,770
-300
| -2% | -$28.4K | 0.38% | 51 |
|
|
2018
Q2 | $1.12M | Hold |
12,070
| – | – | 0.4% | 51 |
|
|
2018
Q1 | $1.14M | Sell |
12,070
-265
| -2% | -$29.1K | 0.41% | 45 |
|
|
2017
Q4 | $1.19M | Hold |
12,335
| – | – | 0.43% | 42 |
|
|
2017
Q3 | $1.1M | Hold |
12,335
| – | – | 0.42% | 45 |
|
|
2017
Q2 | $894K | Sell |
12,335
-1,500
| -11% | -$101K | 0.36% | 54 |
|
|
2017
Q1 | $901K | Sell |
13,835
-200
| -1% | -$12.6K | 0.37% | 55 |
|
|
2016
Q4 | $879K | Sell |
14,035
-100
| -0.7% | -$6.1K | 0.39% | 57 |
|
|
2016
Q3 | $891K | Hold |
14,135
| – | – | 0.39% | 57 |
|
|
2016
Q2 | $875K | Hold |
14,135
| – | – | 0.4% | 56 |
|
|
2016
Q1 | $807K | Buy |
14,135
+1,039
| +8% | +$57.9K | 0.37% | 59 |
|
|
2015
Q4 | $776K | Buy |
13,096
+261
| +2% | +$15K | 0.44% | 58 |
|
|
2015
Q3 | $698K | Sell |
12,835
-100
| -0.8% | -$6.51K | 0.41% | 61 |
|
|
2015
Q2 | $869K | Hold |
12,935
| – | – | 0.49% | 55 |
|
|
2015
Q1 | $757K | Hold |
12,935
| – | – | 0.44% | 59 |
|
|
2014
Q4 | $846K | Buy |
+12,935
| New | +$815K | 0.52% | 55 |
|
Other funds holding ABBV
Cambridge Advisors's ABBV Position: Q2 2026 in Review
Cambridge Advisors reduced its AbbVie (ABBV) stake by 0.47% in Q2 2026, selling an estimated $8.61K and leaving 8,520 shares worth $2.14M. The position accounts for 0.37% of the portfolio, ranked #43.
Cambridge Advisors first reported a position in ABBV in Q4 2014 and has held it in 47 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Cambridge Advisors held 8,520 shares of AbbVie worth $2.14M as of Q2 2026.
- Cambridge Advisors sold 40 AbbVie shares in Q2 2026, an estimated $8.61K.
- AbbVie made up 0.37% of Cambridge Advisors's portfolio in Q2 2026, its #43 holding.
- Cambridge Advisors first reported a position in AbbVie in Q4 2014 and has held it in 47 quarters since.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Cambridge Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.